Camp4 Therapeutics Reports Positive Preclinical Data for Lead Candidate CMP-002 in SYNGAP1-Related Disorder
CAMP has more than doubled off its 52-week low of $1.305 on elevated volume (2.0× avg).
Summary
Camp4 Therapeutics released positive preclinical data for CMP-002, demonstrating improved seizure control in a SYNGAP1-related disorder model, paving the way for a Phase 1/2 clinical trial in 2H 2026.
Key Events · Product Development and Regulatory · CAMP
-
Positive Preclinical Data for CMP-002
New data shows CMP-002 significantly improved seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model.
-
Advancing Lead Candidate to Clinic
The company plans to initiate a Phase 1/2 clinical trial for CMP-002 in individuals with SYNGAP1-related disorder in the second half of 2026.
-
Addressing High Unmet Need
CMP-002 targets SYNGAP1-related disorder, a rare CNS condition with no approved disease-modifying therapies, affecting over 10,000 individuals in the US.
Analysis · CAMP · Life Sciences
Camp4 Therapeutics announced new preclinical data showing its lead therapeutic candidate, CMP-002, significantly improved seizure outcomes in a model of SYNGAP1-related disorder. This strengthens the scientific basis for CMP-002 and supports the company's plan to initiate a Phase 1/2 clinical trial in the second half of 2026, addressing a rare CNS disorder with high unmet medical need.
At the time of this filing, CAMP was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $233.7M. The 52-week trading range was $1.31 to $7.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.